Epigenetic regulation of the human telomerase reverse transciptase gene: A potential therapeutic target for the treatment of leukemia (Review)

Oncology Letters

Volumn 6, Issue 2, 2013, Pages 317-322

  Sui, Xinbing ^a   Kong, Na ^a   Wang, Zhanggui ^a   Pan, Hongming ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b Key Laboratory of Biotherapy of Zhejiang Province   (China)

Author keywords

Epigenetic; Human telomerase reverse transcriptase; Leukemia

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AURORA KINASE INHIBITOR; AZACITIDINE; DEPSIPEPTIDE; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; IMATINIB; MOCETINOSTAT; PANOBINOSTAT; TELOMERASE REVERSE TRANSCRIPTASE; TELOMESTATIN; TRANSCRIPTION FACTOR; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CELL DIFFERENTIATION; CHEMICAL STRUCTURE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DNA METHYLATION; EPIGENETIC REPRESSION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HETEROCHROMATIN; HISTONE ACETYLATION; HUMAN; LEUKEMIA; LEUKEMIA CELL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW;

EID: 84879493810     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1367     Document Type: Review

References (68)

1. de Lange T: Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 19: 2100-2110, 2005.
2. Palm W and de Lange T: How shelterin protects mammalian telomeres. Annu Rev Genet 42: 301-334, 2008.
3. Morin GB: The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59: 521-529, 1989.
4. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ and Reddel RR: Protein composition of catalytically active human telomerase from immortal cells. Science 315: 1850-1853, 2007.
5. Blackburn EH: Switching and signaling at the telomere. Cell 106: 661-673, 2001.
6. Pinto AR, Li H, Nicholls C and Liu JP: Telomere protein complexes and interactions with telomerase in telomere maintenance. Front Biosci 16: 187-207, 2011.
7. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
8. Agrelo R and Wutz A: Cancer progenitors and epigenetic contexts: an Xisting connection. Epigenetics 4: 568-570, 2009.
9. Vineis P, Chuang SC, Vaissière T, Cuenin C, Ricceri F; Genair-EPIC Collaborators, Johansson M, Ueland P, Brennan P and Herceg Z: DNA methylation changes associated with cancer risk factors and blood levels of vitamin metabolites in a prospective study. Epigenetics 6: 195-201, 2011.
10. Laird PW: The power and the promise of DNA methylation markers. Nat Rev Cancer 3: 253-266, 2003.
11. Baylin SB and Ohm JE: Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6: 107-116, 2006.
12. Shao C, Lacey M, Dubeau L and Ehrlich M: Hemimethylation footprints of DNA demethylation in cancer. Epigenetics 4: 165-175, 2009.
13. Sawan C and Herceg Z: Histone modifications and cancer. Adv Genet 70: 57-85, 2010.
14. Rivière G, Lienhard D, Andrieu T, Vieau D, Frey BM and Frey FJ: Epigenetic regulation of somatic angiotensin-converting enzyme by DNA methylation and histone acetylation. Epigenetics 6: 478-489, 2011.
15. Cairney CJ and Keith WN: Telomerase redefined: integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity. Biochimie 90: 13-23, 2008.
16. Dessain SK, Yu H, Reddel RR, Beijersbergen RL and Weinberg RA: Methylation of the human telomerase gene CpG island. Cancer Res 60: 537-541, 2000.
17. Zhu J, Zhao Y and Wang S: Chromatin and epigenetic regulation of the telomerase reverse transcriptase gene. Protein Cell 1: 22-32, 2010.
18. Iliopoulos D, Oikonomou P, Messinis I and Tsezou A: Correlation of promoter hypermethylation in hTERT, DAPK and MGMT genes with cervical oncogenesis progression. Oncol Rep 22: 199-204, 2009.
19. Gigek CO, Leal MF, Silva PN, Lisboa LC, Lima EM, Calcagno DQ, Assumpção PP, Burbano RR and Smith Mde A: hTERT methylation and expression in gastric cancer. Biomarkers 14: 630-636, 2009.
20. Wang S, Hu C and Zhu J: Distinct and temporal roles of nucleosomal remodeling and histone deacetylation in the repression of the hTERT gene. Mol Biol Cell 21: 821-832, 2010.
21. Jia W, Wang S, Horner JW, Wang N, Wang H, Gunther EJ, DePinho RA and Zhu J: A BAC transgenic reporter recapitulates in vivo regulation of human telomerase reverse transcriptase in development and tumorigenesis. FASEB J 25: 979-989, 2011.
22. Baird DM, Rowson J, Wynford-Thomas D and Kipling D: Extensive allelic variation and ultrashort telomeres in senescent human cells. Nat Genet 33: 203-207, 2003.
23. Harley CB, Futcher AB and Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature 345: 458-460, 1990.
24. Li Y, Liu L, Andrews LG and Tollefsbol TO: Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms. Int J Cancer 125: 286-296, 2009.
25. Egger G, Liang G, Aparicio A and Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463, 2004.
26. Lopatina NG, Poole JC, Saldanha SN, Hansen NJ, Key JS, Pita MA, Andrews LG and Tollefsbol TO: Control mechanisms in the regulation of telomerase reverse transcriptase expression in differentiating human teratocarcinoma cells. Biochem Biophys Res Commun 306: 650-659, 2003.
27. Shin KH, Kang MK, Dicterow E and Park NH: Hypermethylation of the hTERT promoter inhibits the expression of telomerase activity in normal oral fibroblasts and senescent normal oral keratinocytes. Br J Cancer 89: 1473-1478, 2003.
28. Zinn RL, Pruitt K, Eguchi S, Baylin SB and Herman JG: hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res 67: 194-201, 2007.
29. Devereux TR, Horikawa I, Anna CH, Annab LA, Afshari CA and Barrett JC: DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res 59: 6087-6090, 1999.
30. Kumari A, Srinivasan R, Vasishta RK and Wig JD: Positive regulation of human telomerase reverse transcriptase gene expression and telomerase activity by DNA methylation in pancreatic cancer. Ann Surg Oncol 16: 1051-1059, 2009.
31. Kumari A, Srinivasan R and Wig JD: Effect of c-MYC and E2F1 gene silencing and of 5-azacytidine treatment on telomerase activity in pancreatic cancer-derived cell lines. Pancreatology 9: 360-368 2009.
32. Guilleret I, Yan P, Grange F, Braunschweig R, Bosman FT and Benhattar J: Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int J Cancer 101: 335-341, 2002.
33. Krajewski WA: Histone acetylation status and DNA sequence modulate ATP-dependent nucleosome repositioning. J Biol Chem 277: 14509-14513, 2002.
34. Lai SR, Phipps SM, Liu L, Andrews LG and Tollefsbol TO: Epigenetic control of telomerase and modes of telomere maintenance in aging and abnormal systems. Front Biosci 10: 1779-1796, 2005.
35. Takakura M, Kyo S, Sowa Y, Wang Z, Yatabe N, Maida Y, Tanaka M and Inoue M: Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res 29: 3006-3011, 2001.
36. Hou M, Wang X, Popov N, Zhang A, Zhao X, Zhou R, Zetterberg A, Björkholm M, Henriksson M, Gruber A and Xu D: The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp Cell Res 274: 25-34, 2002.
37. Murakami J, Asaumi J, Kawai N, Tsujigiwa H, Yanagi Y, Nagatsuka H, Inoue T, Kokeguchi S, Kawasaki S, Kuroda M, Tanaka N, Matsubara N and Kishi K: Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer. Cancer Chemother Pharmacol 56: 22-28, 2005.
38. Zhu K, Qu D, Sakamoto T, Fukasawa I, Hayashi M and Inaba N: Telomerase expression and cell proliferation in ovarian cancer cells induced by histone deacetylase inhibitors. Arch Gynecol Obstet 277: 15-19, 2008.
39. Suenaga M, Soda H, Oka M, Yamaguchi A, Nakatomi K, Shiozawa K, Kawabata S, Kasai T, Yamada Y, Kamihira S, Tei C and Kohno S: Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells. Int J Cancer 97: 621-625, 2002.
40. Khaw AK, Silasudjana M, Banerjee B, Suzuki M, Baskar R and Hande MP: Inhibition of telomerase activity and human telomerase reverse transcriptase gene expression by histone deacetylase inhibitor in human brain cancer cells. Mutat Res 625: 134-144, 2007.
41. Rice JC, Briggs SD, Ueberheide B, Barber CM, Shabanowitz J, Hunt DF, Shinkai Y and Allis CD: Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains. Mol Cell 12: 1591-1598, 2003.
42. Atkinson SP, Hoare SF, Glasspool RM and Keith WN: Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res 65: 7585-7590, 2005.
43. Liu C, Fang X, Ge Z, Jalink M, Kyo S, Björkholm M, GruberA, Sjöberg J and Xu D: The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3. Cancer Res 67: 2626-26, 2007.
44. Röth A, Vercauteren S, Sutherland HJ and Lansdorp PM: Telomerase is limiting the growth of acute myeloid leukemia cells. Leukemia 17: 2410-2417, 2003.
45. Annaloro C, Onida F, Saporiti G and Lambertenghi Deliliers G: Cancer stem cells in hematological disorders: current and possible new therapeutic approaches. Curr Pharm Biotechnol 12: 217-225, 2011.
46. Liu L, Saldanha SN, Pate MS, Andrews LG and TollefsbolTO: Epigenetic regulation of human telomerase reverse transcriptase promoter activity during cellular differentiation. Genes Chromosomes Cancer 41: 26-37, 2004.
47. Bechter OE, Eisterer W, Dlaska M, Kühr T and Thaler J: CpG island methylation of the hTERT promoter is associated with lower telomerase activity in B-cell lymphocytic leukemia. Exp Hematol 30: 26-33, 2002.
48. Terrin L, Trentin L, Degan M, Corradini I, Bertorelle R, CarliP, Maschio N, Bo MD, Noventa F, Gattei V, Semenzato G and DeRossi A: Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome. Leukemia 21: 965-972, 2007.
49. Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, GiagounidisA, Selleslag D, Labar B, Germing U, SalihHR, Beeldens F, Muus P, Pflüger KH, Coens C, HagemeijerA, EckartSchaefer H, Ganser A, Aul C, de Witte T and WijermansPW: Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 29: 1987-1996, 2011.
50. Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, WangES, Gabrilove JL, Garcia-Manero G, Hu K, Franklin JL and BergerDP: Phase 2 study of romiplostim in patients with low-or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 116: 3163-3170, 2010.
51. Baer MR and Gojo I: Novel agents for the treatment of acute myeloid leukemia in the older patient. J Natl Compr Canc Netw9: 331-335, 2011.
52. Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, MacbethKJ, Laille E, Giordano H, Sakoian S, Jabbour E, Kantarjian H and Skikne B: Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 29: 2521-2527, 2011.
53. Claus R and Lübbert M: Epigenetic targets in hematopoietic malignancies. Oncogene 22: 6489-6496, 2003.
54. Lane AA and Chabner BA: Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459-5468, 2009.
55. Pendino F, Sahraoui T, Lanotte M and Ségal-Bendirdjian E: A novel mechanism of retinoic acid resistance in acute promyelocytic leukemia cells through a defective pathway in telomerase regulation. Leukemia 16: 826-832, 2002.
56. Pendino F, Flexor M, Delhommeau F, Buet D, Lanotte M and Segal-Bendirdjian E: Retinoids down-regulate telomerase and telomere length in a pathway distinct from leukemia cell differentiation. Proc Natl Acad Sci USA 98: 6662-6667, 2001.
57. Kretzner L, Scuto A, Dino PM, Kowolik CM, Wu J, Ventura P, Jove R, Forman SJ, Yen Y and Kirschbaum MH: Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res 71: 3912-3920, 2011.
58. Quintás-Cardama A, Santos FP and Garcia-Manero G: Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 25: 226-235, 2011.
59. Azouz A, Wu YL, Hillion J, Tarkanyi I, Karniguian A, AradiJ, Lanotte M, Chen GQ, Chehna M and Ségal-Bendirdjian E: Epigenetic plasticity of hTERT gene promoter determines retinoid capacity to repress telomerase in maturation-resistant acute promyelocytic leukemia cells. Leukemia 24: 613-622, 2010.
60. Love WK, Berletch JB, Andrews LG and Tollefsbol TO: Epigenetic regulation of telomerase in retinoid-induced differentiation of human leukemia cells. Int J Oncol 32: 625-631, 2008.
61. Woo HJ, Lee SJ, Choi BT, Park YM and Choi YH: Induction of apoptosis and inhibition of telomerase activity by trichostatin A, a histone deacetylase inhibitor, in human leukemic U937 cells. Exp Mol Pathol 82: 77-84, 2007.
62. Okabe S, Tauchi T, Nakajima A, Sashida G, Gotoh A, BroxmeyerHE, Ohyashiki JH and Ohyashiki K: Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. Stem Cells Dev 16: 503-514, 2007.
63. Deville L, Hillion J, Pendino F, Samy M, Nguyen E and Ségal-Bendirdjian E: hTERT promotes imatinib resistance in chronic myeloid leukemia cells: therapeutic implications. Mol Cancer Ther 10: 711-719, 2011.
64. Nakajima A, Tauchi T, Sashida G, Sumi M, Abe K, Yamamoto K, Ohyashiki JH and Ohyashiki K: Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy. Leukemia 17: 560-567, 2003.
65. Tauchi T, Shin-ya K, Sashida G, Sumi M, Okabe S, OhyashikiJH and Ohyashiki K: Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. Oncogene 25: 5719-5725, 2006.
66. Altucci L, Clarke N, Nebbioso A, Scognamiglio A and Gronemeyer H: Acute myeloid leukemia: therapeutic impact of epigenetic drugs. Int J Biochem Cell Biol 37: 1752-1762, 2005.
67. Bhalla KN: Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23: 3971-3993, 2005.
68. Piekarz RL and Bates SE: Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res 15: 3918-3926, 2009.